Identification of pyroptosis-related genes and potential drugs in diabetic nephropathy
Diabetic nephropathy (DN) is one of the serious microvascular complications of diabetes mellitus (DM). A growing body of research has demonstrated that the inflammatory state plays a critical role in the incidence and development of DN. Pyroptosis is a new way of programmed cell death, which has the...
Saved in:
Published in | Journal of translational medicine Vol. 21; no. 1; pp. 490 - 17 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central Ltd
21.07.2023
BioMed Central BMC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Diabetic nephropathy (DN) is one of the serious microvascular complications of diabetes mellitus (DM). A growing body of research has demonstrated that the inflammatory state plays a critical role in the incidence and development of DN. Pyroptosis is a new way of programmed cell death, which has the particularity of natural immune inflammation. The inhibition of inflammatory cytokine expression and regulation of pathways related to pyroptosis may be a novel strategy for DN treatment. The aim of this study is to identify pyroptosis-related genes and potential drugs for DN.
DN differentially expressed pyroptosis-related genes were identified via bioinformatic analysis Gene Expression Omnibus (GEO) dataset GSE96804. Dataset GSE30528 and GSE142025 were downloaded to verify pyroptosis-related differentially expressed genes (DEGs). Least absolute shrinkage and selection operator (LASSO) regression analysis was used to construct a pyroptosis-related gene predictive model. A consensus clustering analysis was performed to identify pyroptosis-related DN subtypes. Subsequently, Gene Set Variation Analysis (GSVA), Gene Ontology (GO) function enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were conducted to explore the differences between DN clusters. A protein-protein interaction (PPI) network was used to select hub genes and DGIdb database was utilized to screen potential therapeutic drugs/compounds targeting hub genes.
A total of 24 differentially expressed pyroptosis-related genes were identified in DN. A 16 gene predictive model was conducted via LASSO regression analysis. According to the expression level of these 16 genes, DN cases were divided into two subtypes, and the subtypes are mainly associated with inflammation, activation of immune response and cell metabolism. In addition, we identified 10 hub genes among these subtypes, and predicted 65 potential DN therapeutics that target key genes.
We identified two pyroptosis-related DN clusters and 65 potential therapeutical agents/compounds for DN, which might shed a light on the treatment of DN. |
---|---|
AbstractList | Background Diabetic nephropathy (DN) is one of the serious microvascular complications of diabetes mellitus (DM). A growing body of research has demonstrated that the inflammatory state plays a critical role in the incidence and development of DN. Pyroptosis is a new way of programmed cell death, which has the particularity of natural immune inflammation. The inhibition of inflammatory cytokine expression and regulation of pathways related to pyroptosis may be a novel strategy for DN treatment. The aim of this study is to identify pyroptosis-related genes and potential drugs for DN. Methods DN differentially expressed pyroptosis-related genes were identified via bioinformatic analysis Gene Expression Omnibus (GEO) dataset GSE96804. Dataset GSE30528 and GSE142025 were downloaded to verify pyroptosis-related differentially expressed genes (DEGs). Least absolute shrinkage and selection operator (LASSO) regression analysis was used to construct a pyroptosis-related gene predictive model. A consensus clustering analysis was performed to identify pyroptosis-related DN subtypes. Subsequently, Gene Set Variation Analysis (GSVA), Gene Ontology (GO) function enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were conducted to explore the differences between DN clusters. A protein-protein interaction (PPI) network was used to select hub genes and DGIdb database was utilized to screen potential therapeutic drugs/compounds targeting hub genes. Results A total of 24 differentially expressed pyroptosis-related genes were identified in DN. A 16 gene predictive model was conducted via LASSO regression analysis. According to the expression level of these 16 genes, DN cases were divided into two subtypes, and the subtypes are mainly associated with inflammation, activation of immune response and cell metabolism. In addition, we identified 10 hub genes among these subtypes, and predicted 65 potential DN therapeutics that target key genes. Conclusion We identified two pyroptosis-related DN clusters and 65 potential therapeutical agents/compounds for DN, which might shed a light on the treatment of DN. Keywords: Diabetic nephropathy, Pyroptosis, Lasso regression, Enrichment analysis, Drug-gene prediction BackgroundDiabetic nephropathy (DN) is one of the serious microvascular complications of diabetes mellitus (DM). A growing body of research has demonstrated that the inflammatory state plays a critical role in the incidence and development of DN. Pyroptosis is a new way of programmed cell death, which has the particularity of natural immune inflammation. The inhibition of inflammatory cytokine expression and regulation of pathways related to pyroptosis may be a novel strategy for DN treatment. The aim of this study is to identify pyroptosis-related genes and potential drugs for DN.MethodsDN differentially expressed pyroptosis-related genes were identified via bioinformatic analysis Gene Expression Omnibus (GEO) dataset GSE96804. Dataset GSE30528 and GSE142025 were downloaded to verify pyroptosis-related differentially expressed genes (DEGs). Least absolute shrinkage and selection operator (LASSO) regression analysis was used to construct a pyroptosis-related gene predictive model. A consensus clustering analysis was performed to identify pyroptosis-related DN subtypes. Subsequently, Gene Set Variation Analysis (GSVA), Gene Ontology (GO) function enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were conducted to explore the differences between DN clusters. A protein–protein interaction (PPI) network was used to select hub genes and DGIdb database was utilized to screen potential therapeutic drugs/compounds targeting hub genes.ResultsA total of 24 differentially expressed pyroptosis-related genes were identified in DN. A 16 gene predictive model was conducted via LASSO regression analysis. According to the expression level of these 16 genes, DN cases were divided into two subtypes, and the subtypes are mainly associated with inflammation, activation of immune response and cell metabolism. In addition, we identified 10 hub genes among these subtypes, and predicted 65 potential DN therapeutics that target key genes.ConclusionWe identified two pyroptosis-related DN clusters and 65 potential therapeutical agents/compounds for DN, which might shed a light on the treatment of DN. Diabetic nephropathy (DN) is one of the serious microvascular complications of diabetes mellitus (DM). A growing body of research has demonstrated that the inflammatory state plays a critical role in the incidence and development of DN. Pyroptosis is a new way of programmed cell death, which has the particularity of natural immune inflammation. The inhibition of inflammatory cytokine expression and regulation of pathways related to pyroptosis may be a novel strategy for DN treatment. The aim of this study is to identify pyroptosis-related genes and potential drugs for DN. DN differentially expressed pyroptosis-related genes were identified via bioinformatic analysis Gene Expression Omnibus (GEO) dataset GSE96804. Dataset GSE30528 and GSE142025 were downloaded to verify pyroptosis-related differentially expressed genes (DEGs). Least absolute shrinkage and selection operator (LASSO) regression analysis was used to construct a pyroptosis-related gene predictive model. A consensus clustering analysis was performed to identify pyroptosis-related DN subtypes. Subsequently, Gene Set Variation Analysis (GSVA), Gene Ontology (GO) function enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were conducted to explore the differences between DN clusters. A protein-protein interaction (PPI) network was used to select hub genes and DGIdb database was utilized to screen potential therapeutic drugs/compounds targeting hub genes. A total of 24 differentially expressed pyroptosis-related genes were identified in DN. A 16 gene predictive model was conducted via LASSO regression analysis. According to the expression level of these 16 genes, DN cases were divided into two subtypes, and the subtypes are mainly associated with inflammation, activation of immune response and cell metabolism. In addition, we identified 10 hub genes among these subtypes, and predicted 65 potential DN therapeutics that target key genes. We identified two pyroptosis-related DN clusters and 65 potential therapeutical agents/compounds for DN, which might shed a light on the treatment of DN. Diabetic nephropathy (DN) is one of the serious microvascular complications of diabetes mellitus (DM). A growing body of research has demonstrated that the inflammatory state plays a critical role in the incidence and development of DN. Pyroptosis is a new way of programmed cell death, which has the particularity of natural immune inflammation. The inhibition of inflammatory cytokine expression and regulation of pathways related to pyroptosis may be a novel strategy for DN treatment. The aim of this study is to identify pyroptosis-related genes and potential drugs for DN.BACKGROUNDDiabetic nephropathy (DN) is one of the serious microvascular complications of diabetes mellitus (DM). A growing body of research has demonstrated that the inflammatory state plays a critical role in the incidence and development of DN. Pyroptosis is a new way of programmed cell death, which has the particularity of natural immune inflammation. The inhibition of inflammatory cytokine expression and regulation of pathways related to pyroptosis may be a novel strategy for DN treatment. The aim of this study is to identify pyroptosis-related genes and potential drugs for DN.DN differentially expressed pyroptosis-related genes were identified via bioinformatic analysis Gene Expression Omnibus (GEO) dataset GSE96804. Dataset GSE30528 and GSE142025 were downloaded to verify pyroptosis-related differentially expressed genes (DEGs). Least absolute shrinkage and selection operator (LASSO) regression analysis was used to construct a pyroptosis-related gene predictive model. A consensus clustering analysis was performed to identify pyroptosis-related DN subtypes. Subsequently, Gene Set Variation Analysis (GSVA), Gene Ontology (GO) function enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were conducted to explore the differences between DN clusters. A protein-protein interaction (PPI) network was used to select hub genes and DGIdb database was utilized to screen potential therapeutic drugs/compounds targeting hub genes.METHODSDN differentially expressed pyroptosis-related genes were identified via bioinformatic analysis Gene Expression Omnibus (GEO) dataset GSE96804. Dataset GSE30528 and GSE142025 were downloaded to verify pyroptosis-related differentially expressed genes (DEGs). Least absolute shrinkage and selection operator (LASSO) regression analysis was used to construct a pyroptosis-related gene predictive model. A consensus clustering analysis was performed to identify pyroptosis-related DN subtypes. Subsequently, Gene Set Variation Analysis (GSVA), Gene Ontology (GO) function enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were conducted to explore the differences between DN clusters. A protein-protein interaction (PPI) network was used to select hub genes and DGIdb database was utilized to screen potential therapeutic drugs/compounds targeting hub genes.A total of 24 differentially expressed pyroptosis-related genes were identified in DN. A 16 gene predictive model was conducted via LASSO regression analysis. According to the expression level of these 16 genes, DN cases were divided into two subtypes, and the subtypes are mainly associated with inflammation, activation of immune response and cell metabolism. In addition, we identified 10 hub genes among these subtypes, and predicted 65 potential DN therapeutics that target key genes.RESULTSA total of 24 differentially expressed pyroptosis-related genes were identified in DN. A 16 gene predictive model was conducted via LASSO regression analysis. According to the expression level of these 16 genes, DN cases were divided into two subtypes, and the subtypes are mainly associated with inflammation, activation of immune response and cell metabolism. In addition, we identified 10 hub genes among these subtypes, and predicted 65 potential DN therapeutics that target key genes.We identified two pyroptosis-related DN clusters and 65 potential therapeutical agents/compounds for DN, which might shed a light on the treatment of DN.CONCLUSIONWe identified two pyroptosis-related DN clusters and 65 potential therapeutical agents/compounds for DN, which might shed a light on the treatment of DN. Abstract Background Diabetic nephropathy (DN) is one of the serious microvascular complications of diabetes mellitus (DM). A growing body of research has demonstrated that the inflammatory state plays a critical role in the incidence and development of DN. Pyroptosis is a new way of programmed cell death, which has the particularity of natural immune inflammation. The inhibition of inflammatory cytokine expression and regulation of pathways related to pyroptosis may be a novel strategy for DN treatment. The aim of this study is to identify pyroptosis-related genes and potential drugs for DN. Methods DN differentially expressed pyroptosis-related genes were identified via bioinformatic analysis Gene Expression Omnibus (GEO) dataset GSE96804. Dataset GSE30528 and GSE142025 were downloaded to verify pyroptosis-related differentially expressed genes (DEGs). Least absolute shrinkage and selection operator (LASSO) regression analysis was used to construct a pyroptosis-related gene predictive model. A consensus clustering analysis was performed to identify pyroptosis-related DN subtypes. Subsequently, Gene Set Variation Analysis (GSVA), Gene Ontology (GO) function enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were conducted to explore the differences between DN clusters. A protein–protein interaction (PPI) network was used to select hub genes and DGIdb database was utilized to screen potential therapeutic drugs/compounds targeting hub genes. Results A total of 24 differentially expressed pyroptosis-related genes were identified in DN. A 16 gene predictive model was conducted via LASSO regression analysis. According to the expression level of these 16 genes, DN cases were divided into two subtypes, and the subtypes are mainly associated with inflammation, activation of immune response and cell metabolism. In addition, we identified 10 hub genes among these subtypes, and predicted 65 potential DN therapeutics that target key genes. Conclusion We identified two pyroptosis-related DN clusters and 65 potential therapeutical agents/compounds for DN, which might shed a light on the treatment of DN. Diabetic nephropathy (DN) is one of the serious microvascular complications of diabetes mellitus (DM). A growing body of research has demonstrated that the inflammatory state plays a critical role in the incidence and development of DN. Pyroptosis is a new way of programmed cell death, which has the particularity of natural immune inflammation. The inhibition of inflammatory cytokine expression and regulation of pathways related to pyroptosis may be a novel strategy for DN treatment. The aim of this study is to identify pyroptosis-related genes and potential drugs for DN. DN differentially expressed pyroptosis-related genes were identified via bioinformatic analysis Gene Expression Omnibus (GEO) dataset GSE96804. Dataset GSE30528 and GSE142025 were downloaded to verify pyroptosis-related differentially expressed genes (DEGs). Least absolute shrinkage and selection operator (LASSO) regression analysis was used to construct a pyroptosis-related gene predictive model. A consensus clustering analysis was performed to identify pyroptosis-related DN subtypes. Subsequently, Gene Set Variation Analysis (GSVA), Gene Ontology (GO) function enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were conducted to explore the differences between DN clusters. A protein-protein interaction (PPI) network was used to select hub genes and DGIdb database was utilized to screen potential therapeutic drugs/compounds targeting hub genes. A total of 24 differentially expressed pyroptosis-related genes were identified in DN. A 16 gene predictive model was conducted via LASSO regression analysis. According to the expression level of these 16 genes, DN cases were divided into two subtypes, and the subtypes are mainly associated with inflammation, activation of immune response and cell metabolism. In addition, we identified 10 hub genes among these subtypes, and predicted 65 potential DN therapeutics that target key genes. We identified two pyroptosis-related DN clusters and 65 potential therapeutical agents/compounds for DN, which might shed a light on the treatment of DN. |
ArticleNumber | 490 |
Audience | Academic |
Author | Liu, Yan Lu, Qian Li, Wenwen Wei, Rui Zhang, Yunye Lu, Zihao Huang, Yuqian Yan, Meng Li, Shuwen |
Author_xml | – sequence: 1 givenname: Meng orcidid: 0000-0002-0540-4720 surname: Yan fullname: Yan, Meng – sequence: 2 givenname: Wenwen surname: Li fullname: Li, Wenwen – sequence: 3 givenname: Rui surname: Wei fullname: Wei, Rui – sequence: 4 givenname: Shuwen surname: Li fullname: Li, Shuwen – sequence: 5 givenname: Yan surname: Liu fullname: Liu, Yan – sequence: 6 givenname: Yuqian surname: Huang fullname: Huang, Yuqian – sequence: 7 givenname: Yunye surname: Zhang fullname: Zhang, Yunye – sequence: 8 givenname: Zihao surname: Lu fullname: Lu, Zihao – sequence: 9 givenname: Qian surname: Lu fullname: Lu, Qian |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37480090$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kktv1DAURiNURB_wB1igSGzYpPgRJ_YKVRWPkSqxAbaWY1_PuMrYwc5Qzb_nzkwpnQqhLBw55zv2jb7z6iSmCFX1mpJLSmX3vlCmur4hjDek5YI0d8-qM9r2qhGy704evZ9W56XcEsJa0aoX1SnvW0mIImfVj4WDOAcfrJlDinXy9bTNaZpTCaXJMJoZXL2ECKU20dVTmne8GWuXN8tSh1i7YAaYg60jTCuMmnm1fVk992Ys8Op-vai-f_r47fpLc_P18-L66qaxomvnxnoAYbtO2EEqzlnvLPeMGd85zhQMljpnmCKKyY5aY1vVq0EB89KywTnKL6rFweuSudVTDmuTtzqZoPcbKS-1yXi3EbTlivsOBo6HtdINBs2eC6qkhW5wHl0fDq5pM6zBWZwzm_FIevwlhpVepl-aEt4RLgQa3t0bcvq5gTLrdSgWxtFESJuimWwpYQxJRN8-QW_TJkf8V0gJxhTD5S-1NDhBiD7hwXYn1Ve9kES1aEPq8h8UPg7WwWJnfMD9o8Cbx5M-jPinFgiwA2BzKiWDf0Ao0bvu6UP3NHZP77un7zAkn4RsmPetwuuE8X_R33GG33U |
CitedBy_id | crossref_primary_10_1177_1934578X251321758 crossref_primary_10_12677_acm_2024_14123112 crossref_primary_10_1186_s12964_024_01944_9 crossref_primary_10_56712_latam_v6i1_3314 crossref_primary_10_1016_j_jpba_2024_116449 crossref_primary_10_3389_fimmu_2024_1451486 crossref_primary_10_1007_s12031_025_02327_6 crossref_primary_10_1515_med_2024_0971 crossref_primary_10_4103_jisp_jisp_92_24 crossref_primary_10_4239_wjd_v16_i2_101538 crossref_primary_10_1007_s10142_023_01212_y crossref_primary_10_3390_ijms242015222 |
Cites_doi | 10.1038/s41401-020-00525-z 10.1007/s10157-022-02273-2 10.1017/erm.2021.27 10.1073/pnas.0506580102 10.3389/fimmu.2021.711939 10.1186/s40659-023-00416-7 10.3389/fcell.2021.756340 10.7717/peerj.14826 10.1080/21690707.2016.1255295 10.1155/2020/8838676 10.1038/s41420-023-01452-8 10.18632/oncotarget.25005 10.1016/j.cels.2015.12.004 10.1038/nmeth.3337 10.1007/s00592-010-0178-4 10.1016/j.intimp.2021.108236 10.3389/fphar.2021.780790 10.2147/DMSO.S303151 10.21037/apm-22-212 10.2217/fon-2019-0732 10.1016/j.tcb.2017.05.005 10.1080/13543784.2018.1538352 10.1111/dom.14007 10.1046/j.1523-1755.2000.07715.x 10.3389/fendo.2021.672350 10.1155/2021/1497449 10.7717/peerj.15437 10.1007/s00592-014-0650-7 10.1007/978-1-4939-9841-8_1 10.1016/j.yexcr.2020.112293 10.1016/j.kint.2017.09.020 10.2337/db14-0893 10.1155/2021/5545193 10.1097/01.ASN.0000065640.77499.D7 10.1038/s41420-021-00451-x 10.1111/cpr.12462 10.1111/cpr.13237 10.1007/s10565-023-09790-0 10.3233/ADR-200246 10.1111/cas.15059 10.1038/emm.2016.169 10.3390/ijms21113798 10.1111/bph.15311 10.1038/s41577-019-0228-2 10.1002/JLB.3MR0420-305R 10.1016/j.kint.2017.11.024 10.1016/j.isci.2023.106773 10.1038/s41586-019-1770-6 10.1155/2019/7825804 10.3390/ijms20153711 10.3389/fphar.2022.932205 10.3389/fendo.2022.864407 10.1016/j.ceb.2020.02.004 10.1016/j.brainres.2020.147114 |
ContentType | Journal Article |
Copyright | 2023. The Author(s). COPYRIGHT 2023 BioMed Central Ltd. 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2023 |
Copyright_xml | – notice: 2023. The Author(s). – notice: COPYRIGHT 2023 BioMed Central Ltd. – notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2023 |
DBID | AAYXX CITATION NPM 3V. 7T5 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 5PM DOA |
DOI | 10.1186/s12967-023-04350-w |
DatabaseName | CrossRef PubMed ProQuest Central (Corporate) Immunology Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni Edition) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Medical Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic PubMed |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1479-5876 |
EndPage | 17 |
ExternalDocumentID | oai_doaj_org_article_c393f6eb35cb48dbada2f35198ce6bdf PMC10360355 A758094225 37480090 10_1186_s12967_023_04350_w |
Genre | Journal Article |
GeographicLocations | China |
GeographicLocations_xml | – name: China |
GrantInformation_xml | – fundername: National Natural Science Foundation of China grantid: 81903683 – fundername: ; grantid: 81903683 |
GroupedDBID | --- 0R~ 29L 2WC 53G 5VS 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACIWK ACPRK ACUHS ADBBV ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EBD EBLON EBS ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SBL SOJ TR2 TUS UKHRP WOQ WOW XSB ~8M NPM PJZUB PPXIY PMFND 3V. 7T5 7XB 8FK AZQEC DWQXO H94 K9. PKEHL PQEST PQUKI 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-c564t-cfee5c665cb893327dc3f22af6d329ebc1dda29092861cac4979b9e2f8c2bdd13 |
IEDL.DBID | M48 |
ISSN | 1479-5876 |
IngestDate | Wed Aug 27 01:27:35 EDT 2025 Thu Aug 21 18:37:38 EDT 2025 Fri Jul 11 15:31:31 EDT 2025 Fri Jul 25 07:58:45 EDT 2025 Tue Jun 17 22:19:05 EDT 2025 Tue Jun 10 21:21:35 EDT 2025 Mon Jul 21 05:53:45 EDT 2025 Thu Apr 24 23:10:22 EDT 2025 Tue Jul 01 02:59:40 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Diabetic nephropathy Pyroptosis Enrichment analysis Lasso regression Drug–gene prediction |
Language | English |
License | 2023. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c564t-cfee5c665cb893327dc3f22af6d329ebc1dda29092861cac4979b9e2f8c2bdd13 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0002-0540-4720 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12967-023-04350-w |
PMID | 37480090 |
PQID | 2852292285 |
PQPubID | 43076 |
PageCount | 17 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_c393f6eb35cb48dbada2f35198ce6bdf pubmedcentral_primary_oai_pubmedcentral_nih_gov_10360355 proquest_miscellaneous_2841022553 proquest_journals_2852292285 gale_infotracmisc_A758094225 gale_infotracacademiconefile_A758094225 pubmed_primary_37480090 crossref_primary_10_1186_s12967_023_04350_w crossref_citationtrail_10_1186_s12967_023_04350_w |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2023-07-21 |
PublicationDateYYYYMMDD | 2023-07-21 |
PublicationDate_xml | – month: 07 year: 2023 text: 2023-07-21 day: 21 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | Journal of translational medicine |
PublicationTitleAlternate | J Transl Med |
PublicationYear | 2023 |
Publisher | BioMed Central Ltd BioMed Central BMC |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
References | R Schwarzer (4350_CR30) 2020; 63 H Cao (4350_CR39) 2022; 13 J Zhang (4350_CR38) 2019; 2019 N Nowak (4350_CR44) 2018; 93 A Duni (4350_CR6) 2019; 20 Y Hu (4350_CR40) 2023; 11 LP Liu (4350_CR21) 2021; 9 RM Mason (4350_CR55) 2003; 14 T Matsubara (4350_CR56) 2015; 64 S Wang (4350_CR57) 2018; 51 O Alowolodu (4350_CR50) 2016; 4 B Misselwitz (4350_CR47) 2021; 178 S Rayego-Mateos (4350_CR10) 2020; 21 Y Ye (4350_CR23) 2021; 7 P Broz (4350_CR13) 2020; 20 T Huang (4350_CR52) 2020; 2020 KO Alsaad (4350_CR43) 2017; 28 AM Newman (4350_CR26) 2015; 12 L Li (4350_CR35) 2021; 112 S Fernandez (4350_CR53) 2021; 5 Y Dong (4350_CR51) 2020; 1748 T Fujita (4350_CR34) 2012; 49 G Li (4350_CR20) 2023 R Ke (4350_CR16) 2020; 396 L Zhang (4350_CR46) 2023; 27 L Sun (4350_CR19) 2023; 11 MK Sagoo (4350_CR1) 2020; 2067 M Fritsch (4350_CR31) 2019; 575 W Li (4350_CR12) 2021; 12 X Zheng (4350_CR36) 2021; 12 NM Selby (4350_CR2) 2020; 22 Q Cheng (4350_CR15) 2021; 42 Y Zuo (4350_CR33) 2021; 23 Y Li (4350_CR48) 2018; 9 S Li (4350_CR14) 2023; 9 H Muraoka (4350_CR58) 2019; 27 Y Deng (4350_CR4) 2021; 12 JA Moreno (4350_CR9) 2018; 27 Y Huo (4350_CR54) 2022; 55 SB Kovacs (4350_CR11) 2017; 27 J Chen (4350_CR22) 2022; 2022 X Cui (4350_CR17) 2023; 56 A Liberzon (4350_CR25) 2015; 1 DJ Leehey (4350_CR7) 2000; 77 YH Du (4350_CR8) 2022; 11 J Lee (4350_CR49) 2023; 26 A Subramanian (4350_CR24) 2005; 102 B Ding (4350_CR27) 2021; 2021 N Samsu (4350_CR5) 2021; 2021 J Lei (4350_CR37) 2020; 16 G Pugliese (4350_CR3) 2014; 51 W Zhu (4350_CR18) 2021; 101 Z Li (4350_CR41) 2022; 13 YH Hsu (4350_CR29) 2017; 49 SZ Zhang (4350_CR32) 2019; 23 P Orning (4350_CR28) 2021; 109 B Qin (4350_CR45) 2021; 14 J Eymael (4350_CR42) 2018; 93 |
References_xml | – volume: 42 start-page: 954 year: 2021 ident: 4350_CR15 publication-title: Acta Pharmacol Sin doi: 10.1038/s41401-020-00525-z – volume: 27 start-page: 12 year: 2023 ident: 4350_CR46 publication-title: Clin Exp Nephrol doi: 10.1007/s10157-022-02273-2 – volume: 23 year: 2021 ident: 4350_CR33 publication-title: Expert Rev Mol Med doi: 10.1017/erm.2021.27 – volume: 102 start-page: 15545 year: 2005 ident: 4350_CR24 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0506580102 – volume: 12 year: 2021 ident: 4350_CR36 publication-title: Front Immunol doi: 10.3389/fimmu.2021.711939 – volume: 56 start-page: 5 year: 2023 ident: 4350_CR17 publication-title: Biol Res doi: 10.1186/s40659-023-00416-7 – volume: 9 year: 2021 ident: 4350_CR21 publication-title: Front Cell Dev Biol doi: 10.3389/fcell.2021.756340 – volume: 11 year: 2023 ident: 4350_CR19 publication-title: PeerJ doi: 10.7717/peerj.14826 – volume: 4 year: 2016 ident: 4350_CR50 publication-title: Intrinsically Disord Proteins doi: 10.1080/21690707.2016.1255295 – volume: 2020 start-page: 8838676 year: 2020 ident: 4350_CR52 publication-title: Biomed Res Int doi: 10.1155/2020/8838676 – volume: 9 start-page: 156 year: 2023 ident: 4350_CR14 publication-title: Cell Death Discov doi: 10.1038/s41420-023-01452-8 – volume: 9 start-page: 26586 year: 2018 ident: 4350_CR48 publication-title: Oncotarget doi: 10.18632/oncotarget.25005 – volume: 1 start-page: 417 year: 2015 ident: 4350_CR25 publication-title: Cell Syst doi: 10.1016/j.cels.2015.12.004 – volume: 12 start-page: 453 year: 2015 ident: 4350_CR26 publication-title: Nat Methods doi: 10.1038/nmeth.3337 – volume: 49 start-page: 111 year: 2012 ident: 4350_CR34 publication-title: Acta Diabetol doi: 10.1007/s00592-010-0178-4 – volume: 101 year: 2021 ident: 4350_CR18 publication-title: Int Immunopharmacol doi: 10.1016/j.intimp.2021.108236 – volume: 27 issue: 199–212 year: 2019 ident: 4350_CR58 publication-title: Cell Rep – volume: 12 year: 2021 ident: 4350_CR12 publication-title: Front Pharmacol doi: 10.3389/fphar.2021.780790 – volume: 14 start-page: 1741 year: 2021 ident: 4350_CR45 publication-title: Diabetes Metab Syndr Obes doi: 10.2147/DMSO.S303151 – volume: 11 start-page: 1093 year: 2022 ident: 4350_CR8 publication-title: Ann Palliat Med doi: 10.21037/apm-22-212 – volume: 16 start-page: 307 year: 2020 ident: 4350_CR37 publication-title: Future Oncol doi: 10.2217/fon-2019-0732 – volume: 27 start-page: 673 year: 2017 ident: 4350_CR11 publication-title: Trends Cell Biol doi: 10.1016/j.tcb.2017.05.005 – volume: 27 start-page: 917 year: 2018 ident: 4350_CR9 publication-title: Expert Opin Investig Drugs doi: 10.1080/13543784.2018.1538352 – volume: 22 start-page: 3 issue: Suppl 1 year: 2020 ident: 4350_CR2 publication-title: Diabetes Obes Metab doi: 10.1111/dom.14007 – volume: 77 start-page: S93 year: 2000 ident: 4350_CR7 publication-title: Kidney Int Suppl doi: 10.1046/j.1523-1755.2000.07715.x – volume: 12 year: 2021 ident: 4350_CR4 publication-title: Front Endocrinol (Lausanne) doi: 10.3389/fendo.2021.672350 – volume: 2021 start-page: 1497449 year: 2021 ident: 4350_CR5 publication-title: Biomed Res Int doi: 10.1155/2021/1497449 – volume: 2022 start-page: 4494713 year: 2022 ident: 4350_CR22 publication-title: Oxid Med Cell Longev – volume: 11 year: 2023 ident: 4350_CR40 publication-title: PeerJ doi: 10.7717/peerj.15437 – volume: 51 start-page: 905 year: 2014 ident: 4350_CR3 publication-title: Acta Diabetol doi: 10.1007/s00592-014-0650-7 – volume: 28 start-page: 898 year: 2017 ident: 4350_CR43 publication-title: Saudi J Kidney Dis Transpl – volume: 2067 start-page: 3 year: 2020 ident: 4350_CR1 publication-title: Methods Mol Biol doi: 10.1007/978-1-4939-9841-8_1 – volume: 396 year: 2020 ident: 4350_CR16 publication-title: Exp Cell Res doi: 10.1016/j.yexcr.2020.112293 – volume: 93 start-page: 626 year: 2018 ident: 4350_CR42 publication-title: Kidney Int doi: 10.1016/j.kint.2017.09.020 – volume: 64 start-page: 2978 year: 2015 ident: 4350_CR56 publication-title: Diabetes doi: 10.2337/db14-0893 – volume: 2021 start-page: 5545193 year: 2021 ident: 4350_CR27 publication-title: Evid Based Complement Alternat Med doi: 10.1155/2021/5545193 – volume: 14 start-page: 1358 year: 2003 ident: 4350_CR55 publication-title: J Am Soc Nephrol doi: 10.1097/01.ASN.0000065640.77499.D7 – volume: 7 start-page: 71 year: 2021 ident: 4350_CR23 publication-title: Cell Death Discov doi: 10.1038/s41420-021-00451-x – volume: 51 year: 2018 ident: 4350_CR57 publication-title: Cell Prolif doi: 10.1111/cpr.12462 – volume: 55 year: 2022 ident: 4350_CR54 publication-title: Cell Prolif doi: 10.1111/cpr.13237 – year: 2023 ident: 4350_CR20 publication-title: Cell Biol Toxicol. doi: 10.1007/s10565-023-09790-0 – volume: 5 start-page: 111 year: 2021 ident: 4350_CR53 publication-title: J Alzheimers Dis Rep doi: 10.3233/ADR-200246 – volume: 112 start-page: 3979 year: 2021 ident: 4350_CR35 publication-title: Cancer Sci doi: 10.1111/cas.15059 – volume: 49 year: 2017 ident: 4350_CR29 publication-title: Exp Mol Med doi: 10.1038/emm.2016.169 – volume: 21 start-page: 3798 year: 2020 ident: 4350_CR10 publication-title: Int J Mol Sci. doi: 10.3390/ijms21113798 – volume: 178 start-page: 3140 year: 2021 ident: 4350_CR47 publication-title: Br J Pharmacol doi: 10.1111/bph.15311 – volume: 20 start-page: 143 year: 2020 ident: 4350_CR13 publication-title: Nat Rev Immunol doi: 10.1038/s41577-019-0228-2 – volume: 109 start-page: 121 year: 2021 ident: 4350_CR28 publication-title: J Leukoc Biol doi: 10.1002/JLB.3MR0420-305R – volume: 93 start-page: 1198 year: 2018 ident: 4350_CR44 publication-title: Kidney Int doi: 10.1016/j.kint.2017.11.024 – volume: 23 start-page: 1248 year: 2019 ident: 4350_CR32 publication-title: Eur Rev Med Pharmacol Sci – volume: 26 start-page: 106773 year: 2023 ident: 4350_CR49 publication-title: iScience. doi: 10.1016/j.isci.2023.106773 – volume: 575 start-page: 683 year: 2019 ident: 4350_CR31 publication-title: Nature doi: 10.1038/s41586-019-1770-6 – volume: 2019 start-page: 7825804 year: 2019 ident: 4350_CR38 publication-title: J Diabetes Res doi: 10.1155/2019/7825804 – volume: 20 start-page: 3711 year: 2019 ident: 4350_CR6 publication-title: Int J Mol Sci. doi: 10.3390/ijms20153711 – volume: 13 year: 2022 ident: 4350_CR39 publication-title: Front Pharmacol doi: 10.3389/fphar.2022.932205 – volume: 13 year: 2022 ident: 4350_CR41 publication-title: Front Endocrinol (Lausanne) doi: 10.3389/fendo.2022.864407 – volume: 63 start-page: 186 year: 2020 ident: 4350_CR30 publication-title: Curr Opin Cell Biol doi: 10.1016/j.ceb.2020.02.004 – volume: 1748 year: 2020 ident: 4350_CR51 publication-title: Brain Res doi: 10.1016/j.brainres.2020.147114 |
SSID | ssj0024549 |
Score | 2.4646413 |
Snippet | Diabetic nephropathy (DN) is one of the serious microvascular complications of diabetes mellitus (DM). A growing body of research has demonstrated that the... Background Diabetic nephropathy (DN) is one of the serious microvascular complications of diabetes mellitus (DM). A growing body of research has demonstrated... BackgroundDiabetic nephropathy (DN) is one of the serious microvascular complications of diabetes mellitus (DM). A growing body of research has demonstrated... Abstract Background Diabetic nephropathy (DN) is one of the serious microvascular complications of diabetes mellitus (DM). A growing body of research has... |
SourceID | doaj pubmedcentral proquest gale pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 490 |
SubjectTerms | Analysis Apoptosis Care and treatment Cell death Clustering Correlation analysis Cytokines Datasets Diabetes Diabetes mellitus Diabetic nephropathies Diabetic nephropathy Diagnosis Drug delivery Drugs Drug–gene prediction Enrichment analysis Gene expression Genetic aspects Genomes Health aspects Immune response Immunosuppressive agents Inflammation Kidney diseases Lasso regression Microvasculature Nephropathy Oxidative stress Pathogenesis Prediction models Protein-protein interactions Pyroptosis Regression analysis Signal transduction |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Na9VAEF-kB_Ei1s_UKisIHmRpstlsssdWLEXQk5Xelv2sDyQJL3mU_vfOZJPHC4JePAXeTkJmdj5-kzc7Q8h7KbDAj3tWmsoxYUTJLMQhVjuuIB_BqatTle83eXUtvtxUNwejvrAmLLUHToI7c6Uqo4SUr3JWNN4ab3jEqXKNC9L6iN4XYt6STC1d9iDtWY7INPJsgKgGDgHiE8sBH-TsbhWGpm79f_rkg6C0Lpg8iECXT8jjGTrS8_TKx-RBaJ-Sh1_nP8efkR_p0G2cv8LRLtL-ftv1YzdsBjYdWgme3qJzo6b1tO9GpIdH-u3udqCblqYvsRtH29Dj_ASAh_fPyfXl5--frtg8NoG5SoqRuRhC5aQEgQEYKXntXRk5N1H6kqtgXeFBhgp2qJGFM06oWlkVeGwct94X5Qty1HZteEWoVbkDWUaACUo46a2qorQIMkxteDAZKRYpajf3FMfRFr_0lFs0UifJa5C8niSv7zLycX9Pnzpq_JX6AjdnT4ndsKcfQEf0rCP6XzqSkQ-4tRptFl4PeE5HD4BJ7H6lzyFpAgbBtWXkdEUJtubWy4ty6NnWB80bwLCKwyUj7_bLeCfWr7Wh2yGNwNS6qsqMvEy6tGcJGwAB0s0z0qy0bMXzeqXd_Jw6gReAP3JAjCf_Q0qvySM-WUjNeHFKjsbtLrwBxDXat5Nx_QaGnSqq priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA96gvgifls9JYLgg4RrkzRtnuQUj0PQJ0_2LeRzXZC2brsc998703b3rgj3VGimpTOZzPwmncwQ8l5JTPDjgQlbeiatFMyBH2KV5xriEey6Omb5_lDnF_LbqlzNG279nFa5t4mjoQ6txz3yE14DUtAcLp-6vwy7RuHf1bmFxl1yD0uXYUpXtboOuCQEP_uDMrU66cG3gVkAL8VyQAk5u1w4o7Fm__-W-YZrWqZN3vBDZ4_IwxlA0tNpxh-TO7F5Qu5_n3-RPyW_pqO3ad6Lo22i3dW27Ya23_RsPLoSA12jiaO2CbRrB6SHV4btbt3TTUOn_diNp03ssIsCgMSrZ-Ti7OvPL-dsbp7AfKnkwHyKsfRKld4BJBG8Cl4kzm1SQXAdnS9CsFzDPNWq8NZLXWmnI0-15y6EQjwnR03bxJeEOp17kGUCsKClV8HpMimHUMNWlkebkWIvRePnyuLY4OKPGSOMWplJ8gYkb0bJm8uMfDw80011NW6l_oyTc6DEmtjjjXa7NvMSM15okVR0AliWdXAW-EvYf7D2UbmQMvIBp9bgyoXPA56nAwjAJNbAMqcQOgGDYOAycryghBXnl8N75TDziu_NtX5m5N1hGJ_ELLYmtjukkRhgl6XIyItJlw4sYRkgwLt5RuqFli14Xo40m99jPfACUEgOuPHV7d_1mjzgo-5XjBfH5GjY7uIbQFSDezsum3_NYiAz priority: 102 providerName: ProQuest |
Title | Identification of pyroptosis-related genes and potential drugs in diabetic nephropathy |
URI | https://www.ncbi.nlm.nih.gov/pubmed/37480090 https://www.proquest.com/docview/2852292285 https://www.proquest.com/docview/2841022553 https://pubmed.ncbi.nlm.nih.gov/PMC10360355 https://doaj.org/article/c393f6eb35cb48dbada2f35198ce6bdf |
Volume | 21 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swED_6AaUvY99z1wUPBnsY2mzZlq2HMZrRUgYtoywj7EVYX1mg2Fni0Oa_30m2s5qVPezFButkfLo73e9k6Q7gDUvdBj-qSVJmiqRlmhCJfojkinKMR1zVVb_L95KdT9Iv02y6A325o24AV_eGdq6e1GR5_f721-YTGvxHb_AF-7BCn4Xmjt6HROj9I3KzC_vomXJnqBdp8Sf3HgZD_cGZe_sdwoFLx4K4Ixr4KZ_O_-9J-47XGu6ovOOizh7Cgw5bhietMjyCHVM9hoOL7u_5E_jensq13TJdWNtwsVnWi6ZezVfEn2oxOpy52S8sKx0u6sbR4yv1cj1bhfMqbJdq5yqszMIVWED8uHkKk7PTb5_PSVdXgaiMpQ1R1phMMZYpiWgloblWiaW0tEwnlBupYq1LylGEBYtVqVKec8kNtYWiUus4eQZ7VV2ZFxBKHikcVos4gqeKackzy6RDIWVeUlMGEPejKFSXdNzVvrgWPvgomGiFIFAIwgtB3ATwbttn0abc-Cf12AlnS-nSZfsH9XImOusTKuGJZUYmyHJaaFkif9aVJiyUYVLbAN460QqnZvh5yHN7NgGZdOmxxAlGVcggzn0BHA8o0RjVsLlXDtHrsqAFglxO8RbA622z6-k2uFWmXjua1MXeWZYE8LzVpS1LvUoGUAy0bMDzsKWa__SpwmMEKBFCyqP_7_oSDqk3kZzQ-Bj2muXavEIg1sgR7ObTfAT749PLr1cjv5wx8haH16vxj9-44DWW |
linkProvider | Scholars Portal |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR1da9RAcKhXUF_Eb6NVIyg-yNLLJtlLHkRabbna9hBppW9r9us8kCRe7jjuT_kbncnHtUHoW58C2UnIzM7nZj4A3oqIEvy4YWEWaxZlUcgU2iE20jzFeISmrtZZvhMxPo--XsQXW_C3q4WhtMpOJ9aK2hSazsh3eYKeQsrx8qn8w2hqFP1d7UZoNGxxbNcrDNmqj0dfcH_fcX54cPZ5zNqpAkzHIlow7ayNtRCxVjRqno-MDh3nmRMm5KlVOjAm4ykikIhAZzpKR6lKLXeJ5sqYIMT33oLtKMRQZgDb-weTb98vu_thuNWV5iRit0JriooI7SIbol8yZKue-aunBPxvC64Yw36i5hXLd3gf7rUuq7_X8NgD2LL5Q7h92v6UfwQ_mmJf157--YXzy_W8KBdFNatYXSxjjT8lpepnufHLYkHw-EozX04rf5b7zQnwTPu5LWluA7ql68dwfiOEfQKDvMjtM_BVOtRIS4fuSRppYVQaO6HIuclGGbeZB0FHRanbXuY0UuO3rGOaRMiG8hIpL2vKy5UHHzbPlE0nj2uh92lzNpDUhbu-UcynshVqqcM0dMKqEFGOEqMyxM_RxMNEW6GM8-A9ba0kXYGfhzg3JQ-IJHXdknsYrCGCqFI92OlBoozr_nLHHLLVMZW8lAgP3myW6UnKm8ttsSSYiEL6OA49eNrw0gYlajyEHvbQg6THZT2c-yv57FfdgTxAv2eInurz67_rNdwZn52eyJOjyfELuMtrORgxHuzAYDFf2pfozy3Uq1aIfPh503L7D2pTYDY |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Identification+of+pyroptosis-related+genes+and+potential+drugs+in+diabetic+nephropathy&rft.jtitle=Journal+of+translational+medicine&rft.au=Yan%2C+Meng&rft.au=Li%2C+Wenwen&rft.au=Wei%2C+Rui&rft.au=Li%2C+Shuwen&rft.date=2023-07-21&rft.pub=BioMed+Central&rft.eissn=1479-5876&rft.volume=21&rft_id=info:doi/10.1186%2Fs12967-023-04350-w&rft_id=info%3Apmid%2F37480090&rft.externalDocID=PMC10360355 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1479-5876&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1479-5876&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1479-5876&client=summon |